Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Wedbush issued their Q3 2024 earnings estimates for Oruka Therapeutics in a research note issued on Thursday, September 12th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.20) for the quarter. Wedbush has a “Strong-Buy” rating on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($2.17) EPS and FY2028 earnings at ($2.92) EPS.

Several other research analysts have also recently weighed in on the stock. Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday. They issued an “outperform” rating and a $41.00 price target on the stock. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday. They set a “buy” rating and a $40.00 target price on the stock. Finally, TD Cowen initiated coverage on Oruka Therapeutics in a research note on Monday. They issued a “buy” rating for the company.

Oruka Therapeutics Trading Up 4.1 %

Shares of NASDAQ ORKA opened at $25.90 on Monday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.